Daisy Petal™ systems installed in GMP space to enable perfusion fermentation at SIIPL, enabling faster, higher-yield protein production in a compact, user-friendly platform.
Collaboration advances the commercialization of a 10-valent HPV vaccine.
Platform to advance the large-scale production and purification of virus-like particles (VLPs) for use in cost-effective human vaccines.
Sunflower Therapeutics (Sunflower), a public benefit corporation transforming global access to protein manufacturing capacity for diverse applications, announced today that it has engaged Alflow Scandinavia A/S as its exclusive distributor for the Daisy Petal™ Perfusion Bioreactor System in Denmark, Norway, Sweden, and Iceland. This marks Sunflower’s first commercial partnership in Europe, representing a key step in its international growth strategy.
The system is installed in the newly commissioned BioBuilder Learning Lab space in Allston Labworks for use in training local students, educators, and incumbent workers to be a passionate part of the growing biotechnology workforce.
Customers in California, Oregon, Washington, Idaho, Montana, and British Columbia can now purchase the Daisy Petal™
Daisy Petal™ is now commercially launched and available for sale in India, Singapore, Thailand, Indonesia, Malaysia, and South Korea
Sunflower Therapeutics (Sunflower), a public benefit corporation transforming global access to protein manufacturing capacity for diverse applications, announced today the oversubscription of a $3M Simple Agreement for Future Equity (SAFE), which underscores ongoing support for the company’s commercial goals.
Recognizing Innovation in Global Life Sciences and Biotechnology HINGHAM, MA, NOVEMBER 19, 2024 ‒ At Sunflower Therapeutics, we’re on a mission to make protein production more accessible, efficient, and cost-effective, and it’s exciting to see our efforts recognized!...
Sunflower Therapeutics, a public benefit corporation transforming global access to protein manufacturing capacity for diverse applications, today announced that SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, has participated in Sunflower’s simple agreement for future equity (SAFE), a flexible agreement providing future equity rights without immediate valuation, with a $2M subscription to solidify their support for the companies’ ongoing research and development R&D collaborations.